Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset, but management are optimistic about rebuilding BME sales channel. DexCom's newest G7 CGM competes closely ...
Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...
DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...
Feb 8 (Reuters) - Glucose monitor maker Dexcom (DXCM.O), opens new tab beat analyst estimates for fourth-quarter earnings on Thursday, helped by strong demand for its continuous glucose monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback